evidence/gaps
Cochrane · systematic review · CD004851

Newer generation antidepressants for depressive disorders in children and adolescents

Hetrick, SE, McKenzie, JE, Cox, GR, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library

Common Mental DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 40%Very low 0 · 0%Low 2 · 40%Moderate 1 · 20%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Second generation antidepressant versus placebo (by medication) for depressive disorders in children and adolescents

Population: patients with depressive disorders in children and adolescents
5 questions
OutcomeEffectEvidenceStatus / GRADE
Depressive disorder according to DSM or ICD criteriaClinician diagnostic interview
Second generation antidepressant vs placebo (by medication)
no estimate extracted0 studies · 0 participantsUngraded
Suicide completionCompleted suicide rates
Second generation antidepressant vs placebo (by medication)
no estimate extracted0 studies · 0 participantsUngraded
Remission or response (as defined in trial)
Second generation antidepressant vs placebo (by medication)
RR 1.18 [1.08, 1.28]16 studies · 2924 participantsModerate
Downgraded: risk of bias
Suicide‐related outcome
Second generation antidepressant vs placebo (by medication)
RR 1.58 [1.02, 2.45]17 studies · 3229 participantsLow
Downgraded: risk of bias
Depressive symptom severityCDRS‐R. Scale from: 17 to 113.
Second generation antidepressant vs placebo (by medication)
no estimate extracted14 studies · 2490 participantsLow
Downgraded: risk of bias